- Home
- PMCB vs LRHC Comparison
PMCB vs LRHC Comparison
Compare PMCB & LRHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMCB
- LRHC
- Stock Information
- Founded
- PMCB 1996
- LRHC 2004
- Country
- PMCB United States
- LRHC United States
- Employees
- PMCB N/A
- LRHC N/A
- Industry
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- LRHC
- Sector
- PMCB Health Care
- LRHC
- Exchange
- PMCB Nasdaq
- LRHC Nasdaq
- Market Cap
- PMCB 6.6M
- LRHC 5.4M
- IPO Year
- PMCB N/A
- LRHC 2023
- Fundamental
- Price
- PMCB $0.94
- LRHC $6.61
- Analyst Decision
- PMCB
- LRHC
- Analyst Count
- PMCB 0
- LRHC 0
- Target Price
- PMCB N/A
- LRHC N/A
- AVG Volume (30 Days)
- PMCB 118.7K
- LRHC 37.5K
- Earning Date
- PMCB 09-12-2025
- LRHC 08-18-2025
- Dividend Yield
- PMCB N/A
- LRHC N/A
- EPS Growth
- PMCB N/A
- LRHC N/A
- EPS
- PMCB 3.19
- LRHC N/A
- Revenue
- PMCB N/A
- LRHC $78,037,079.00
- Revenue This Year
- PMCB N/A
- LRHC N/A
- Revenue Next Year
- PMCB N/A
- LRHC N/A
- P/E Ratio
- PMCB $0.30
- LRHC N/A
- Revenue Growth
- PMCB N/A
- LRHC 54.92
- 52 Week Low
- PMCB $0.80
- LRHC $4.33
- 52 Week High
- PMCB $2.42
- LRHC $142.40
- Technical
- Relative Strength Index (RSI)
- PMCB 47.20
- LRHC 56.41
- Support Level
- PMCB $0.92
- LRHC $5.57
- Resistance Level
- PMCB $1.00
- LRHC $6.12
- Average True Range (ATR)
- PMCB 0.09
- LRHC 0.48
- MACD
- PMCB 0.00
- LRHC 0.19
- Stochastic Oscillator
- PMCB 28.69
- LRHC 94.51
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
About LRHC La Rosa Holdings Corp.
La Rosa Holdings Corp operates in the U.S. residential real estate market. It is a holding company for agent-centric, technology-integrated, cloud-based, multi-service real estate companies. The company's business is organized based on the services it provides internally to the agents and to the public, which are residential and commercial real estate brokerage, franchising, real estate brokerage education and coaching, and property management. The company has six reportable segments, namely: Real Estate Brokerage Services (Residential), Franchising Services, Coaching Services, Property Management, Real Estate Brokerage Services (Commercial), and Title Settlement and Insurance. It derives maximum revenue from the Real Estate Brokerage Services (Residential) segment.